
On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Subscribe





